InnovaPharm Flexamend: Potent Anti-Inflammatory Joint Support

Published on May 30, 2024 by PricePlow Staff | No Comments

We all want to stay active, and more specifically, to keep doing what we’ve always done in the gym. But two things can happen over time:

InnovaPharm Flexamend PricePlow

InnovaPharm Flexamend is a powerful anti-inflammatory joint support supplement with several clinically-validated ingredients

  1. We train aggressively and tend to push our muscles — and thus joints — to certain limits, sometimes damaging the latter in a quest to grow the former.
  2. We age. We may love lifting heavy when we’re young, but the older we get, the harder it is to pull off without getting hurt.

Either way, the victim of our quest for gains often comes in the price of our joint health.

InnovaPharm Flexamend: Support Your Joints with Innovation

So, with that in mind, InnovaPharm has given us a very nifty joint support formula – Flexamend, which is absolutely jam-packed with powerful anti-inflammatory ingredients.

One thing we love about this formula is the abundance of randomized controlled trials backing the main ingredients.

So now after you blow it up with their incredible new pump supplement, Poppa Pump, your joints will need a bit of support to get back in there and do it again.

Let’s get into how it works but first, check PricePlow for product pricing and availability, and sign up for our InnovaPharm news and deals, these guys have been innovating like crazy lately:

InnovaPharm Flexamend – Deals and Price Drop Alerts

Get Price Alerts

No spam, no scams.

Disclosure: PricePlow relies on pricing from stores with which we have a business relationship. We work hard to keep pricing current, but you may find a better offer.

Posts are sponsored in part by the retailers and/or brands listed on this page.

This area is reserved for Team PricePlow's upcoming videos.

Subscribe to our channel and sign up for notifications so you catch it when it goes live!

Subscribe to PricePlow on YouTube!

InnovaPharm Flexamend Ingredients

In a single 2 capsule serving of InnovaPharm Flexamend, you get the following:

  • Curcumin C3 Reduct (Curcuma longa) (rhizomes) (standardized to minimum 95% tetrahydrocurcuminoids) – 400 mg

    InnovaPharm Flexamend Ingredients

    Curcumin is a brightly colored orange pigment that gives turmeric its instantly-recognizable color.[1] The word “curcumin” most often refers to a particular molecule, but it’s important to recognize that curcumin is only one in a large family of compounds called the curcuminoids. The curcuminoids as a whole are powerfully anti-inflammatory.[2] This is why turmeric root, which is rich in curcuminoids, has been employed for millennia by traditional medicine systems including Ayurvedic medicine.[3]

    In addition to decreasing inflammation,[4-9] curcuminoids are also potent antioxidants.[1,10-15] This shouldn’t surprise anyone, given the close connection between inflammation and oxidative stress.[16]

    Inflammation and oxidative stress are powerful therapeutic targets, with lots of downstream benefits. Because of this, curcuminoids have been recognized by researchers for their ability to improve liver, cardiovascular, and neurological health.[17]

    How curcuminoids downregulate inflammation – cyclooxygenase-2 (COX-2)

    Just to put the power of the curcuminoids into perspective, these bioactive constituents have been shown to inhibit cyclooxygenase-2 (COX-2),[18-21] a pro-inflammatory enzyme[22] that’s also targeted by famous non-steroidal anti-inflammatory drugs aspirin and ibuprofen. Like these NSAIDs, curcuminoids have been shown to substantially decrease the severity of chronic pain.[4,9,14,23-33]

    Curcuminoids and joint health

    There are quite a few studies showing that curcuminoid supplementation can help improve the severity of osteoarthritis symptoms.[4,9,14,23-33]

    In one of these studies, a randomized controlled trial, 500 milligrams of turmeric extract per day for 4 months decreased the incidence of joint crepitation by 60%, joint stiffness by 64%, and joint effusion by 76%.[34] In other words – just to be clear – of the patients who began this study with active knee crepitation, 60% of them saw it go into remission by the end of the study period.

    Focusing on tetrahydrocurcumin

    InnovaPharm Flexamend

    While we don’t exactly have the above 500 milligram dose, we are quite close — and this is no standard “turmeric extract” — InnovaPharm selected a standardization of 95% tetrahydrocurcuminoids, highly-bioavailable metabolites that the body actually forms when you take curcumin orally.[35-38]

    This “side-stepping” by taking the metabolite provides a few benefits, since you get more of the active ingredient inside. Of note, a few different pathways are more highly-targeted,[37] and there may even be some metabolic benefits![38]

    Additionally, many brands and manufacturers appreciate that tetrahydrocurcumin is white,[39] and dieters enjoy that it combats harmful lipid peroxidation.[40] The latter of which, we’re starting to believe, will support joint health as well. We’ll take it all!

  • Palmitoylethanolamide (PEA) – 400 mg

    Palmitoylethanolamide (PEA) is a lipid molecule with demonstrated anti-inflammatory, pain-relieving, anti-microbial, immunomodulatory, and neuroprotective effects.[41] One really cool thing about PEA is that your body actually synthesizes it endogenously from palmitic acid, a type of lipid that occurs naturally in coconut oil, meat, and dairy products.[34]

    But since your body only creates as much PEA as it needs at any given time, this means that it’s almost always possible to derive additional benefit from supplemental, exogenous PEA. This is especially true if you’re a vegan or vegetarian, as restricting animal product intake is likely to downregulate endogenous PEA production.

    As of the time of this writing, PubMed has indexed over 350 peer-reviewed journal articles about PEA’s benefits for human health. Some of these papers discuss the fact that PEA has been used as a medicine in many parts of the world – e.g., PEA has been used to in flu and cold patients,[34] has been identified as a possible therapy for irritable bowel syndrome,[42] and has also been studied for use in autoimmune and neurological diseases.[34,43,44]

    When we see such diverse benefits, we think two things:

    InnovaPharm Flexamend

    1. It combats systemic inflammation
    2. It supports liver health

    And that indeed seems to be the case in terms of inflammation: PEA’s many applications and benefits share one thing in common – PEA’s natural anti-inflammatory activity. One meta-analysis, published by the Journal of Pain Research, concluded that PEA is a viable therapy for managing chronic and neuropathic pain.[43]

    A research review published by the same journal concluded that PEA supplementation is safe and effective for dealing with nerve compression syndromes like sciatica and carpal tunnel.[44]

    The PEA mechanism of action: an endocannabinoid!

    PEA downregulates inflammation by agonizing proliferator-activated receptor alpha (PPAR-α), which signals your body to decrease its production of inflammatory cytokines.[43]

    But what makes PEA really distinctive is its ability to active your body’s endocannabinoid system,[43] which is responsible for the runner’s high euphoria that can be triggered by vigorous exercise.[45]

    The endocannabinoid system has also been studied for the management of arthritic joint pain. One study found that activating the endocannabinoid system may actually halt the progression of arthritis.[46]

    This makes sense because endocannabinoids are themselves anti-inflammatory.[43,45,46] Furthermore, PEA can decrease the activity of mast cells, which play a central role in the inflammatory response.[47]

  • Boswellin Super (Boswellia Serrata Extract) (Indian Frankincense Resin Extract) (standardized to 75% Boswellic Acids and 30% AKBA) – 100 mg

    Boswellia contains four different boswellic acids, the most powerful of which is called acetyl-11-keto-beta-boswellic acid (AKBA). The boswellic acids, including AKBA, have been shown to exert potent anti-inflammatory effects.[48]

    Boswellin Plus Logo

    The boswellic acids, including AKBA, are known to downregulate an enzyme called 5-lipoxygenase (LOX-5),[49,50] which triggers the creation of toxic lipid peroxides from polyunsaturated fatty acids (PUFAs) in a process known as lipid peroxidation. It’s an extremely inflammatory process,[51-53] so decreasing LOX-5 activity is one of the most powerful anti-inflammatory mechanisms at our disposal.

    As it turns out, boswellia is a great ingredient to pair with COX inhibitors like curcumin (see above) – combination COX and LOX-5 inhibitor compounds are known to be extremely good at downregulation inflammatory processes, and have been collectively identified as a serious contender to be the next-generation non-steroidal anti-inflammatory drugs (NSAIDs).[54] Needless to say, we’re thrilled to see curcumin and boswellia show up together in InnovaPharm Flexamend.

    Other research indicates that AKBA can decrease the body’s production of inflammatory cytokines like tumor necrosis factor alpha (TNF-α).[55-57]

    Management of osteoarthritis

    One randomized, double-blind, placebo-controlled study showed that Boswellia extract can dose-dependently improve patient scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), an inventory designed to measure the intensity of knee pain.[58]

    Boswellia Benefits: Pain and Stiffness

    Study participants who took 100 mg or 250 mg of a standardized Boswellia serrata extract daily saw significant improvements in their scores on the WOMAC index, an inventory used to measure knee pain in osteoarthritis patients.[58]

    Boswellia MMP-3

    The Boswellia extract downregulated an enzyme that breaks down collagen.[58]

    The same study showed that the Boswellia extract can inhibit matrix metalloproteinase 3 (MMP-3), an enzyme that degrades collagen and tends to be overexpressed in OA patients.[58] Given that collagen is an important building block for joint tissue, it’s not shocking that this mechanism would be implicated.

    At least two other RCTS have shared similar findings.[59,60]

  • Ginger Root Extract (Zingiber Officinale Extract) (standardized to 5% Gingerols) – 100 mg

    Ginger is a close relative of turmeric and, like turmeric, has impressive anti-inflammatory effects.[61,62]

    Certain bioactive constituents in ginger, like its gingerols and shogaols, are known to decrease the production of proinflammatory cytokines like interleukins 1 and 8 (IL-1, IL-8) and tumor necrosis factor alpha (TNF-α). They do this through some mechanisms of action we’ve already discussed in this article – namely, LOX-5 and COX inhibition.[63,64]

    One shogaol in particular, 6-shogaol, has been shown to downregulate inducible nitric oxide synthase (iNOS), an enzyme that generates NO in a stress hormone context,[65] as opposed to endothelial nitric oxide synthase (eNOS), which generates the good, cardioprotective, vasodilatory kind of NO.

    Ginger Knee Pain

    In a randomized controlled trial, OA patients who consumed ginger extract reported a significantly greater reduction in knee pain than the placebo group.[66]

    One study showed that OA patients who randomly received either 255 mg of ginger extract, or a placebo, saw significant improvements in reported knee pain and WOMAC score by the end of the 6-week study period.[66] The effect sizes were pretty impressive – the ginger group saw an average 13 point reduction, compared to the placebo’s 9 point improvement.[66] The ginger group also experienced substantially less knee pain when standing and walking 50 feet.[66]

  • AstraGin (Astragalus membranaceus (root), Panax notoginseng (root) – 50 mg

    AstraGin is a patented[67-71] combination of botanical extracts sourced from Chinese ginseng and astragalus – two plants that are absolutely loaded with bioactive constituents that improve gastrointestinal function.

    AstraGin

    The bioactives in AstraGin have been shown to increase the amount of adenosine triphosphate (ATP) produced by human intestinal cells. Once those cells have access to the extra ATP, they can use that cellular energy to absorb more nutrients from the food and supplements that are passing through the digestive tract.

    Thus, AstraGin is hoped to increase the bioavailability of whatever you take it with.

    When taken regularly over long periods of time, AstraGin can even improve gastrointestinal health.[72]

  • BioPerine (Black Pepper Fruit Extract) (standardized to 95% Piperine) – 50 mg

    Piperine, the primary bioactive constituent of BioPerine black pepper extract, is another bioavailability-enhancing ingredient like AstraGin. The key bioactive constituent here is piperine, an alkaloid that’s been shown to inhibit the action of certain stomach enzymes. When those enzymes are less active, ingested nutrients are able to transit your stomach intact, thus increasing their absorption by the intestines.[35]

    Bioperine

    Piperine can also benefit metabolic health a bit – it’s increases insulin sensitivity by activating glucose transporter 4 (GLUT4),[36] and can discourage the accumulation of fat in your liver.[37] It’s also a powerful antioxidant.[38]

    Incredible synergy with curcumin

    So if BioPerine and AstraGin are both bioavailability enhancers, why do we need the two of them in the same formula?

    As it turns out, piperine is unbelievably good at increasing the bioavailability of curcumin specifically. While curcumin is hamstrung by low oral bioavailability when taken on its own,[39] BioPerine has been shown to increase curcumin’s absorption by an absolutely incredible 2,000%.[40]

Dosage and Directions

Take one serving once daily. There are many strategies with an anti-inflammatory supplement like this:

  • 1 Capsule in the AM, 1 Capsule in the PM (12-hour shifts for the ingredients)
  • Take before bed for improved sleep from the PEA
  • Consider pre-workout if you have serious joint pain. Note, however, that this may reduce muscle inflammation, which we want when training, so this is our least-preferred method.

Conclusion: Potent Anti-Inflammatory for post Poppa Pump

The InnovaPharm Flexamend formula might be short, but it’s also sweet. We have some really awesome synergy here, with multiple ingredients inhibiting LOX-5 and COX, plus the very smart inclusion of BioPerine in addition to AstraGin for the curumin-specific bioavailability boost.

InnovaPharm 2024 New Product Lineup

In this formula, we also have three different ingredients – curcumin, boswellia, and ginger root extract – that have been validated as efficacious specifically for joint problems by randomized, double-blind, placebo-controlled studies. This type of study design is the gold standard in medical and nutritional research, so we always feel confident in a product that’s based on RCT-backed ingredients.

If you’re feeling seriously inflamed, there’s no supplement we’d rather try first.

Overall, this is one of those products that illustrates how ingredient quality can be much more important than quantity.

InnovaPharm Flexamend – Deals and Price Drop Alerts

Get Price Alerts

No spam, no scams.

Disclosure: PricePlow relies on pricing from stores with which we have a business relationship. We work hard to keep pricing current, but you may find a better offer.

Posts are sponsored in part by the retailers and/or brands listed on this page.

About the Author: PricePlow Staff

PricePlow Staff

PricePlow is a team of supplement industry veterans that include medical students, competitive strength athletes, and scientific researchers who all became involved with dieting and supplements out of personal need.

The team's collective experiences and research target athletic performance and body composition goals, relying on low-toxicity meat-based diets.

No Comments | Posted in | Tagged , , , , , , , , , , , .

References

  1. DiSilvestro, Robert A, et al. “Diverse Effects of a Low Dose Supplement of Lipidated Curcumin in Healthy Middle Aged People.” Nutrition Journal, vol. 11, no. 1, 26 Sept. 2012, 10.1186/1475-2891-11-79; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518252/
  2. Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives – A review. J Tradit Complement Med. 2016 Jun 15;7(2):205-233. doi: 10.1016/j.jtcme.2016.05.005; https://pubmed.ncbi.nlm.nih.gov/28417091/
  3. Jayaprakasha, G.K., et al. “Chemistry and Biological Activities of C. Longa.” Trends in Food Science & Technology, vol. 16, no. 12, Dec. 2005, pp. 533–548, 10.1016/j.tifs.2005.08.006; https://www.sciencedirect.com/science/article/abs/pii/S0924224405002049
  4. Belcaro, Gianni, et al. “Efficacy and Safety of Meriva®, a Curcumin-Phosphatidylcholine Complex, during Extended Administration in Osteoarthritis Patients.” Alternative Medicine Review: A Journal of Clinical Therapeutic, vol. 15, no. 4, 1 Dec. 2010, pp. 337–344; https://pubmed.ncbi.nlm.nih.gov/21194249/
  5. Chainani-Wu, Nita, et al. “High-Dose Curcuminoids Are Efficacious in the Reduction in Symptoms and Signs of Oral Lichen Planus.” Journal of the American Academy of Dermatology, vol. 66, no. 5, May 2012, pp. 752–760, 10.1016/j.jaad.2011.04.022; https://pubmed.ncbi.nlm.nih.gov/21907450/
  6. Khajehdehi, Parviz, et al. “Oral Supplementation of Turmeric Attenuates Proteinuria, Transforming Growth Factor-β and Interleukin-8 Levels in Patients with Overt Type 2 Diabetic Nephropathy: A Randomized, Double-Blind and Placebo-Controlled Study.” Scandinavian Journal of Urology and Nephrology, vol. 45, no. 5, 31 May 2011, pp. 365–370, 10.3109/00365599.2011.585622; https://pubmed.ncbi.nlm.nih.gov/21627399/
  7. Khajehdehi, Parviz, et al. “Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering from Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-Controlled Study.” Journal of Renal Nutrition, vol. 22, no. 1, Jan. 2012, pp. 50–57, 10.1053/j.jrn.2011.03.002; https://pubmed.ncbi.nlm.nih.gov/21742514/
  8. Hanai, Hiroyuki, et al. “Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.” Clinical Gastroenterology and Hepatology, vol. 4, no. 12, Dec. 2006, pp. 1502–1506, 10.1016/j.cgh.2006.08.008; https://pubmed.ncbi.nlm.nih.gov/17101300/
  9. Amalraj, Augustine, et al. “A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.” Journal of Medicinal Food, vol. 20, no. 10, 2017, pp. 1022–1030, 10.1089/jmf.2017.3930; https://pubmed.ncbi.nlm.nih.gov/28850308/
  10. Prasad, S., & Aggarwal, B. (2011). Turmeric, the Golden Spice. Oxidative Stress and Disease Herbal Medicine, 263-288. doi:10.1201/b10787-14; https://www.ncbi.nlm.nih.gov/books/NBK92752/
  11. Kalpravidh, Ruchaneekorn W., et al. “Improvement in Oxidative Stress and Antioxidant Parameters in Beta-Thalassemia/Hb E Patients Treated with Curcuminoids.” Clinical Biochemistry, vol. 43, no. 4-5, 1 Mar. 2010, pp. 424–429, 10.1016/j.clinbiochem.2009.10.057; https://pubmed.ncbi.nlm.nih.gov/19900435/
  12. Baum, Larry, et al. “Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients with Alzheimer Disease.” Journal of Clinical Psychopharmacology, vol. 28, no. 1, Feb. 2008, pp. 110–113, 10.1097/jcp.0b013e318160862c; https://pubmed.ncbi.nlm.nih.gov/18204357/
  13. Biswas, Jaydip, et al. “Curcumin Protects DNA Damage in a Chronically Arsenic-Exposed Population of West Bengal.” Human & Experimental Toxicology, vol. 29, no. 6, 1 June 2010, pp. 513–524, 10.1177/0960327109359020; https://pubmed.ncbi.nlm.nih.gov/20056736/
  14. Srivastava, Shobhit, et al. “Curcuma Longa Extract Reduces Inflammatory and Oxidative Stress Biomarkers in Osteoarthritis of Knee: A Four-Month, Double-Blind, Randomized, Placebo-Controlled Trial.” Inflammopharmacology, vol. 24, no. 6, 19 Oct. 2016, pp. 377–388, 10.1007/s10787-016-0289-9; https://pubmed.ncbi.nlm.nih.gov/27761693/
  15. T Krishnareddy, Naveen, et al. “A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, Randomized, Placebo-Controlled Study.” BioMed Research International, vol. 2018, 2018, p. 9159281, 10.1155/2018/9159281; https://pubmed.ncbi.nlm.nih.gov/30345312/
  16. Lugrin, Jérôme et al. “The role of oxidative stress during inflammatory processes.” Biological chemistry vol. 395,2 (2014): 203-30. doi:10.1515/hsz-2013-0241 https://www.degruyter.com/document/doi/10.1515/hsz-2013-0241/html
  17. Xu XY, Meng X, Li S, Gan RY, Li Y, Li HB. Bioactivity, Health Benefits, and Related Molecular Mechanisms of Curcumin: Current Progress, Challenges, and Perspectives. Nutrients. 2018 Oct 19;10(10):1553. doi: 10.3390/nu10101553; https://pubmed.ncbi.nlm.nih.gov/30347782/
  18. Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018). Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytotherapy Research, 32(6), 985-995; doi:10.1002/ptr.6054; https://onlinelibrary.wiley.com/doi/10.1002/ptr.6054
  19. Camacho-Barquero, Laura, et al. “Curcumin, a Curcuma Longa Constituent, Acts on MAPK P38 Pathway Modulating COX-2 and INOS Expression in Chronic Experimental Colitis.” International Immunopharmacology, vol. 7, no. 3, Mar. 2007, pp. 333–342, 10.1016/j.intimp.2006.11.006; https://pubmed.ncbi.nlm.nih.gov/17276891/
  20. Aggarwal, Sita, et al. “Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IkappaBalpha Kinase and Akt Activation.” Molecular Pharmacology, vol. 69, no. 1, 2006, pp. 195–206, 10.1124/mol.105.017400; https://pubmed.ncbi.nlm.nih.gov/16219905/
  21. Li, Cheng et al. “Curcuminoids: Implication for inflammation and oxidative stress in cardiovascular diseases.” Phytotherapy research: PTR vol. 33,5 (2019): 1302-1317. doi:10.1002/ptr.6324; https://onlinelibrary.wiley.com/doi/10.1002/ptr.6324
  22. Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther. 2009 Aug;8(8):2348-55. doi: 10.1158/1535-7163.MCT-09-0290; https://pubmed.ncbi.nlm.nih.gov/19671757/
  23. Panahi, Yunes, et al. “Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial.” Phytotherapy Research, vol. 28, no. 11, 22 May 2014, pp. 1625–1631, 10.1002/ptr.5174; https://pubmed.ncbi.nlm.nih.gov/24853120/
  24. Belcaro, G., et al. “Product-Evaluation Registry of Meriva®, a Curcumin-Phosphatidylcholine Complex, for the Complementary Management of Osteoarthritis.” Panminerva Medica, vol. 52, no. 2 Suppl 1, 1 June 2010, pp. 55–62; https://pubmed.ncbi.nlm.nih.gov/20657536/
  25. Togni, et al. “Comparative Evaluation of the Pain-Relieving Properties of a Lecithinized Formulation of Curcumin (Meriva®), Nimesulide, and Acetaminophen.” Journal of Pain Research, Mar. 2013, p. 201, 10.2147/jpr.s42184; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596124/
  26. Agarwal, Krishna Adit, et al. “Efficacy of Turmeric (Curcumin) in Pain and Postoperative Fatigue after Laparoscopic Cholecystectomy: A Double-Blind, Randomized Placebo-Controlled Study.” Surgical Endoscopy, vol. 25, no. 12, 14 June 2011, pp. 3805–3810, 10.1007/s00464-011-1793-z; https://pubmed.ncbi.nlm.nih.gov/21671126/
  27. Madhu, K., et al. “Safety and Efficacy of Curcuma Longa Extract in the Treatment of Painful Knee Osteoarthritis: A Randomized Placebo-Controlled Trial.” Inflammopharmacology, vol. 21, no. 2, 16 Dec. 2012, pp. 129–136, 10.1007/s10787-012-0163-3; https://pubmed.ncbi.nlm.nih.gov/23242572/
  28. Nakagawa, Yasuaki, et al. “Short-Term Effects of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Prospective Study.” Journal of Orthopaedic Science, vol. 19, no. 6, Nov. 2014, pp. 933–939, 10.1007/s00776-014-0633-0; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244558/
  29. Haroyan, Armine, et al. “Efficacy and Safety of Curcumin and Its Combination with Boswellic Acid in Osteoarthritis: A Comparative, Randomized, Double-Blind, Placebo-Controlled Study.” BMC Complementary and Alternative Medicine, vol. 18, no. 1, 9 Jan. 2018, 10.1186/s12906-017-2062-z; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761198/
  30. Kuptniratsaikul, Vilai, et al. “Efficacy and Safety of Curcuma Domestica Extracts Compared with Ibuprofen in Patients with Knee Osteoarthritis: A Multicenter Study.” Clinical Interventions in Aging, vol. 9, Mar. 2014, p. 451, 10.2147/cia.s58535; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964021/
  31. Panda, Sanjib kumar, et al. “A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA.” BioMed Research International, vol. 2018, 25 Oct. 2018, pp. 1–8, 10.1155/2018/5291945; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222223/
  32. Chandran, Binu, and Ajay Goel. “A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis.” Phytotherapy Research, vol. 26, no. 11, 9 Mar. 2012, pp. 1719–1725, 10.1002/ptr.4639; https://pubmed.ncbi.nlm.nih.gov/22407780/
  33. Shep, Dhaneshwar, et al. “Safety and Efficacy of Curcumin versus Diclofenac in Knee Osteoarthritis: A Randomized Open-Label Parallel-Arm Study.” Trials, vol. 20, no. 1, 11 Apr. 2019, 10.1186/s13063-019-3327-2; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460672/
  34. Keppel Hesselink, J. et al. Aug. 2013. “Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold.” International Journal of Inflammation vol. 2013. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771453/
  35. Kiuchi, F., et al. “Nematocidal Activity of Turmeric: Synergistic Action of Curcuminoids.” Chemical & Pharmaceutical Bulletin, vol. 41, no. 9, 1 Sept. 1993, pp. 1640–1643, 10.1248/cpb.41.1640; https://pubmed.ncbi.nlm.nih.gov/8221978/
  36. Changtam, Chatchawan, et al. “Curcuminoid Analogs with Potent Activity against Trypanosoma and Leishmania Species.” European Journal of Medicinal Chemistry, vol. 45, no. 3, 1 Mar. 2010, pp. 941–956, 10.1016/j.ejmech.2009.11.035; https://pubmed.ncbi.nlm.nih.gov/20004045/
  37. Aggarwal, Bharat B et al; “Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.”; Molecules (Basel, Switzerland); vol. 20,1; 185-205; 24 Dec. 2014; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272158/
  38. Ireson, Christopher R., et al. “Metabolism of the Cancer Chemopreventive Agent Curcumin in Human and Rat Intestine.” Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, vol. 11, no. 1, 1 Jan. 2002, pp. 105–111. https://pubmed.ncbi.nlm.nih.gov/11815407/
  39. Pan, M H et al; “Biotransformation of curcumin through reduction and glucuronidation in mice.”; Drug metabolism and disposition: the biological fate of chemicals; vol. 27,4; 1999; 486-94; https://pubmed.ncbi.nlm.nih.gov/10101144/
  40. Khopde, Sujata M., et al. “Inhibition of Radiation-Induced Lipid Peroxidation by Tetrahydrocurcumin: Possible Mechanisms by Pulse Radiolysis.” Bioscience, Biotechnology, and Biochemistry, vol. 64, no. 3, Jan. 2000, pp. 503–509, doi:10.1271/bbb.64.503. https://pubmed.ncbi.nlm.nih.gov/10803946/
  41. Clayton, Paul et al. “Palmitoylethanolamide: A Natural Compound for Health Management.” International journal of molecular sciences vol. 22,10 5305. 18 May. 2021, doi:10.3390/ijms22105305 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157570/#sec9-ijms-22-05305
  42. Brugnatelli, Viola et al. “Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment.” Frontiers in neuroscience vol. 14 371. 21 Apr. 2020, doi:10.3389/fnins.2020.00371 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186328/
  43. Keppel Hesselink, J. et al. Oct. 2012. “Therapeutic Utility of Palmitoylethanolamide in The Treatment of Neuropathic Pain Associated with Various Pathological Conditions: A Case Series.” Journal of Pain Research vol. 5; 437-42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500919/
  44. Keppel Hesselink, J. et al. Oct. 2015. “Palmitoylethanolamide, A Neutraceutical, in Nerve Compression Syndromes: Efficacy and Safety in Sciatic Pain and Carpal Tunnel Syndrome.” Journal of Pain Research vol. 8; 729-34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631430/
  45. Raichlen, David A et al. “Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the ‘runner’s high’.” The Journal of experimental biology vol. 215,Pt 8 (2012): 1331-6. doi:10.1242/jeb.063677 https://pubmed.ncbi.nlm.nih.gov/22442371/
  46. Barrie, Nicola, and Nicholas Manolios. “The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.” European journal of rheumatology vol. 4,3 (2017): 210-218. doi:10.5152/eurjrheum.2017.17025 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685274/
  47. Skaper S. et al. Oct. 2013. “Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator.” Molecular Neurobiology vol. 48,2; 340-52. https://pubmed.ncbi.nlm.nih.gov/23813098/
  48. Singh, G B, and C K Atal. “Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent.” Agents and actions vol. 18,3-4 (1986): 407-12. doi:10.1007/BF01965005; https://link.springer.com/article/10.1007/BF01965005
  49. ‌Safayhi, H et al. “Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.” The Journal of pharmacology and experimental therapeutics vol. 261,3 (1992): 1143-6. https://jpet.aspetjournals.org/content/261/3/1143.long
  50. Sailer, E R et al. “Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity.” British journal of pharmacology vol. 117,4 (1996): 615-8. doi:10.1111/j.1476-5381.1996.tb15235.x; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1909340/
  51. Zhong, Shanshan et al. “An update on lipid oxidation and inflammation in cardiovascular diseases.” Free radical biology & medicine vol. 144 (2019): 266-278. doi:10.1016/j.freeradbiomed.2019.03.036; https://linkinghub.elsevier.com/retrieve/pii/S0891-5849(19)30271-0
  52. Dias, Irundika H K et al. “Inflammation, Lipid (Per)oxidation, and Redox Regulation.” Antioxidants & redox signaling vol. 33,3 (2020): 166-190. doi:10.1089/ars.2020.8022; https://www.liebertpub.com/doi/10.1089/ars.2020.8022
  53. Leong, Xin-Fang. “Lipid Oxidation Products on Inflammation-Mediated Hypertension and Atherosclerosis: A Mini Review.” Frontiers in nutrition vol. 8 717740. 30 Sep. 2021, doi:10.3389/fnut.2021.717740; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514637/
  54. Martel-Pelletier, J. “Therapeutic Role of Dual Inhibitors of 5-LOX and COX, Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs.” Annals of the Rheumatic Diseases, vol. 62, no. 6, 1 June 2003, pp. 501–509, doi:10.1136/ard.62.6.501; https://ard.bmj.com/content/62/6/501
  55. Roy, Sashwati et al. “Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells.” DNA and cell biology vol. 24,4 (2005): 244-55. doi:10.1089/dna.2005.24.244; https://www.liebertpub.com/doi/10.1089/dna.2005.24.244
  56. Syrovets, Tatiana et al. “Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases.” Journal of immunology (Baltimore, Md. : 1950) vol. 174,1 (2005): 498-506. doi:10.4049/jimmunol.174.1.498; https://journals.aai.org/jimmunol/article/174/1/498/72237/Acetyl-Boswellic-Acids-Inhibit-Lipopolysaccharide
  57. Roy, Sashwati et al. “Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to antiinflammatory Boswellia.” Antioxidants & redox signaling vol. 8,3-4 (2006): 653-60. doi:10.1089/ars.2006.8.653; https://www.liebertpub.com/doi/10.1089/ars.2006.8.653
  58. Sengupta, Krishanu et al. “A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.” Arthritis research & therapy vol. 10,4 (2008): R85. doi:10.1186/ar2461; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575633/
  59. Kimmatkar, N et al. “Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial.” Phytomedicine : international journal of phytotherapy and phytopharmacology vol. 10,1 (2003): 3-7. doi:10.1078/094471103321648593; https://www.sciencedirect.com/science/article/abs/pii/S0944711304701890
  60. Sengupta, Krishanu et al. “Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study.” International journal of medical sciences vol. 7,6 366-77. 1 Nov. 2010, doi:10.7150/ijms.7.366; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974165/
  61. Mashhadi, Nafiseh Shokri et al. “Anti-oxidative and anti-inflammatory effects of ginger in health and physical activity: review of current evidence.” International journal of preventive medicine vol. 4,Suppl 1 (2013): S36-42; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665023/
  62. Bliddal, H, et al. “A Randomized, Placebo-Controlled, Cross-over Study of Ginger Extracts and Ibuprofen in Osteoarthritis.” Osteoarthritis and Cartilage, vol. 8, no. 1, Jan. 2000, pp. 9–12, 10.1053/joca.1999.0264; https://pubmed.ncbi.nlm.nih.gov/10607493/
  63. Tjendraputra, E et al. “Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells.” Bioorganic chemistry vol. 29,3 (2001): 156-63. doi:10.1006/bioo.2001.1208; https://www.sciencedirect.com/science/article/abs/pii/S0045206801912088
  64. Verma, S K et al. “Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits.” Indian journal of experimental biology vol. 42,7 (2004): 736-8. https://nopr.niscpr.res.in/bitstream/123456789/23544/1/IJEB%2042(7)%20736-738.pdf
  65. Pan, Min-Hsiung et al. “6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression.” Molecular nutrition & food research vol. 52,5 (2008): 527-37. doi:10.1002/mnfr.200700157 https://onlinelibrary.wiley.com/doi/10.1002/mnfr.200700157
  66. Altman, R D, and K C Marcussen. “Effects of a ginger extract on knee pain in patients with osteoarthritis.” Arthritis and rheumatism vol. 44,11 (2001): 2531-8. doi:10.1002/1529-0131(200111)44:11<2531::aid-art433>3.0.co;2-j https://onlinelibrary.wiley.com/doi/epdf/10.1002/1529-0131%28200111%2944%3A11%3C2531%3A%3AAID-ART433%3E3.0.CO%3B2-J
  67. Lin, Hang-Ching, et al. “Method for Regulating Nutrient Absorption with Ginsenosides”; United States Patent and Trademark Office; Patent US20090181904A1; July 16, 2009; https://patents.google.com/patent/US20090181904A1/
  68. Lin, Hang-Ching, et al. “Method for Enhancing Nutrient Absorption with Astragalosides”; United States Patent and Trademark Office; Patent US20120196816A1; August 2, 2012; https://patents.google.com/patent/US20120196816A1/
  69. Lin, Hang-Ching, et al. “Method for Enhancing Nutrient Absorption with Astragalosides”; United States Patent and Trademark Office; Patent US20120196817A1; August 2, 2012; https://patents.google.com/patent/US20120196817A1/
  70. Lin, Hang-Ching, et al. “Method for Enhancing Nutrient Absorption with Astragalosides”; United States Patent and Trademark Office; Patent US8197860B2; June 12, 2012; https://patents.google.com/patent/US8197860B2/en
  71. Lin, Hang-Ching, et al. “Compound for enhancing nutrients uptake”; Taiwan Intellectual Property Office; Patent TWI271195B; 28-Dec 2004; https://patents.google.com/patent/TWI271195B/en
  72. Lee, Shih-Yu, et al. “Astragaloside II Promotes Intestinal Epithelial Repair by Enhancing L-Arginine Uptake and Activating the MTOR Pathway.” Scientific Reports, vol. 7, no. 1, 26 Sept. 2017, p. 12302, 10.1038/s41598-017-12435-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614914/

Comments and Discussion (Powered by the PricePlow Forum)